Oral Formulations and Lipophilic Salts of Methylnaltrexone

Wyeth, LLC

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 6 of these applications claim priority to application 61/313,018, filed Mar 11, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Patent	Title	Holder	Status	Expires	Time remaining	Confidence
US 8,524,276	Oral Formulations and Lipophilic Salts of Methylnaltrexone Wyeth, LLC In force Term ends Mar 10, 2031 · High confidence	Wyeth, LLC	In force	Term ends Mar 10, 2031	Term ends Mar 10, 2031	High confidence
US 8,956,651	Oral Formulations and Lipophilic Salts of Methylnaltrexone Wyeth, LLC In force Ends no later than Mar 10, 2031 · Medium confidence	Wyeth, LLC	In force	Ends no later than Mar 10, 2031	Ends no later than Mar 10, 2031	Medium confidence
US 9,314,461	Oral Formulations and Lipophilic Salts of Methylnaltrexone Wyeth, LLC In force Term ends Mar 10, 2031 · Medium confidence	Wyeth, LLC	In force	Term ends Mar 10, 2031	Term ends Mar 10, 2031	Medium confidence
US 10,307,417	Oral Formulations and Lipophilic Salts of Methylnaltrexone Wyeth, LLC In force Ends no later than Mar 10, 2031 · Medium confidence	Wyeth, LLC	In force	Ends no later than Mar 10, 2031	Ends no later than Mar 10, 2031	Medium confidence
US 10,376,505	Oral Formulations and Lipophilic Salts of Methylnaltrexone Wyeth, LLC In force Ends no later than Mar 10, 2031 · Medium confidence	Wyeth, LLC	In force	Ends no later than Mar 10, 2031	Ends no later than Mar 10, 2031	Medium confidence
US 10,507,206	Oral Formulations and Lipophilic Salts of Methylnaltrexone Wyeth, LLC In force Ends no later than Mar 10, 2031 · Medium confidence	Wyeth, LLC	In force	Ends no later than Mar 10, 2031	Ends no later than Mar 10, 2031	Medium confidence
Application 15/070,555	Oral Formulations and Lipophilic Salts of Methylnaltrexone Wyeth, LLC Abandoned Abandoned Jan 7, 2019	Wyeth, LLC	Abandoned	Abandoned Jan 7, 2019	not computed
Application 16/664,239	Oral Formulations and Lipophilic Salts of Methylnaltrexone Wyeth, LLC Abandoned Abandoned Jan 9, 2024	Wyeth, LLC	Abandoned	Abandoned Jan 9, 2024	not computed

8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

6 of these are in force and held by Wyeth, LLC.

Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.